These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 3958753)

  • 21. [Phase II study of recombinant human interferon gamma (S-6810) in renal cell carcinoma. Urological Cooperative Study Group of Recombinant Human Interferon Gamma (S-6810)].
    Machida T; Koiso K; Takaku F; Ogawa M
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):440-5. PubMed ID: 3101607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon.
    Small EJ; Weiss GR; Malik UK; Walther PJ; Johnson D; Wilding G; Kuzel T; Bajamonde A; Paton V
    Cancer J Sci Am; 1998; 4(3):162-7. PubMed ID: 9612597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of metastatic renal cell carcinoma with a combination of human lymphoblastoid interferon-alpha and cimetidine.
    Kotake T; Kinouchi T; Saiki S; Kuroda M; Miki T; Kiyohara H; Usami M
    Jpn J Clin Oncol; 1991 Feb; 21(1):46-51. PubMed ID: 2067120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration.
    Muss HB; Costanzi JJ; Leavitt R; Williams RD; Kempf RA; Pollard R; Ozer H; Zekan PJ; Grunberg SM; Mitchell MS
    J Clin Oncol; 1987 Feb; 5(2):286-91. PubMed ID: 3543247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma].
    Noguchi S; Shuin T; Kubota Y; Masuda M; Yao M; Hosaka M
    Hinyokika Kiyo; 1995 Jul; 41(7):517-20. PubMed ID: 7668181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of pulmonary metastasis from renal cell carcinoma in which complete remission was achieved by interferon therapy (r-IFN-alpha A, Ro 22-8181)].
    Ishito N; Wada F; Aramaki K; Asano S; Johsen T
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):380-3. PubMed ID: 3947113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
    Culine S; Iborra F; Mottet N; Avancès C; de Graeve B; Volpé P; Vignoud J; Bringer JP; Marroncle M; Le Pellec L; Ayuso D; Jansen E; Faix A; Rebillard X
    Am J Clin Oncol; 2006 Apr; 29(2):148-52. PubMed ID: 16601433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of recombinant interferon alpha-C in patients with metastatic renal cell carcinoma.
    Merimsky O; Inbar M; Merimsky E; Kovner F; Spitzer E; Laufer R; Braf Z; Chaitchik S
    Mol Biother; 1990 Sep; 2(3):155-9. PubMed ID: 2222899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of recombinant alpha-interferon on advanced renal cell carcinoma].
    Isaka S; Okano T; Akimoto S; Shimazaki J; Murakami S; Igarashi T; Kitamura Y; Yamaguchi K; Kataumi S; Ohtsuka K
    Hinyokika Kiyo; 1985 Dec; 31(12):2209-14. PubMed ID: 3832921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II study. Subcommittee on Urogenital Malignancy, Committee on MHR-24 against Tumors].
    Niijima T; Akaza H; Koyanagi T; Togashi M; Kumamoto Y; Funyu T; Suzuki T; Orikasa S; Yoshikawa K; Koiso K
    Hinyokika Kiyo; 1992 Oct; 38(10):1201-7. PubMed ID: 1481783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.
    Naglieri E; Gebbia V; Durini E; Lelli G; Abbate I; Selvaggi FP; Di Tonno P; Colucci G
    Anticancer Res; 1998; 18(3B):2021-6. PubMed ID: 9677460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell therapy in combination with interferon-alpha for the treatment of metastatic renal cell carcinoma.
    Tatsugami K; Eto M; Harano M; Hamaguchi M; Miyamoto T; Morisaki T; Furue M; Akashi K; Naito S
    Int J Urol; 2008 Aug; 15(8):694-8. PubMed ID: 18564205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial].
    Jacqmin D; Bergerat JP; Dufour P; Bollack C; Prévot G; Jurascheck F; Bailly G; Degaris S; Oberling F
    J Urol (Paris); 1987; 93(8):463-6. PubMed ID: 3440838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with subcutaneous interleukin-2 and interferon-alpha in advanced renal cancer patients with poor prognostic factors.
    Canobbio L; Curotto A; Cannata D; Miglietta L; Lavarello A; Giglio C; Franchini R; Cussotto M; Boccardo F
    Anticancer Res; 1996; 16(1):541-4. PubMed ID: 8615668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Tubiana N; Ouldkaci M; Prevot G; Lucas V; Oudard S; Malet M; Cottu P; Ferrero JM; Mayeur D; Rixe O; Sun XS; Bernard O; Andre T; Tournigand C; Muracciole X; Guilhot J;
    J Clin Oncol; 2003 Nov; 21(21):3987-94. PubMed ID: 14581421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
    Amato RJ; Morgan M; Rawat A
    Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical phase II trial of recombinant DNA interferon (interferon alpha 2b) in patients with metastatic malignant melanoma.
    Dorval T; Palangie T; Jouve M; Garcia-Giralt E; Israel L; Falcoff E; Schwab D; Pouillart P
    Cancer; 1986 Jul; 58(2):215-8. PubMed ID: 3719515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.